Intensity Q2 2026 net loss $3.0M; resumes sarcoma and TNBC trials

INTENSITY THERAPEUTICS, INC.

2026-Q2 EPS reported -$2.08

Q2 2026 net loss $3.0M vs $2.5M in Q2 2025; R&D $1.8M, G&A $1.3M.
Cash $9.5M at June 30; raised $1.6M net from ATM in Q2, $1.3M more after quarter end.
Phase 3 INVINCIBLE-3 resumed enrollment activities in April 2026 after FDA-reviewed protocol amendment; 21 patients previously enrolled.
Phase 2 INVINCIBLE-4 restarted treatment in July 2026; preliminary pCR 71% vs 42% for SOC; full enrollment targeted by end 2027.
Opened first France site for INVINCIBLE-4; increased business development activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.